Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOHONOS (palovarotene) is an oral retinoid capsule approved by the FDA in August 2023 for rare genetic skeletal disorders characterized by abnormal bone formation. It represents a novel therapeutic approach targeting retinoid signaling pathways to modulate heterotopic ossification and related conditions. The drug addresses a significant unmet medical need in ultra-rare patient populations with limited treatment options.
Peak10.8 years to LOE
As a newly launched specialty product in peak phase with minimal competitive pressure, the brand team is likely expanding to build awareness and access in a niche rare disease market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on SOHONOS at Ipsen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.